(19) World Intellectual Property **Organization** International Bureau





(43) International Publication Date 24 February 2005 (24.02.2005)

PCT

(10) International Publication Number WO 2005/015990 A1

(51) International Patent Classification7:

A01K 67/027

(21) International Application Number:

PCT/SE2004/001209

(22) International Filing Date: 18 August 2004 (18.08.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/481,249 18 August 2003 (18.08.2003) US 60/481,608 7 November 2003 (07.11.2003) US 60/521,377 14 April 2004 (14.04.2004)

- (71) Applicants (for all designated States except US): BE-TAGENON AB [SE/SE]; P O Box 2339, S-103 18 STOCKHOLM (SE). YEDA RESEARCH AND DE-VELOPMENT CO LTD [IL/IL]; P O Box 95, 76100 REHOVOT (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EDLUND, Helena [SE/SE]; Mellanbågen 18, S-907 38 UMEÅ (SE). WALKER, Michael D. [IL/IL]; 40 Sderot Hen, Apartment 12, 76469 REHOVOT (IL). RUBINS, Nir [IL/IL]; 2 Neve Alon Street, Apartment 29, 76455 REHOVOT (IL). STENEBERG, Pär [SE/SE]; Kustvägen 73, S-905 80 UMEĂ (SE).

- (74) Agent: ALBIHNS STOCKHOLM AB; P.O. Box 5581. S-114 85 Stockholm (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO. CR. CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW DIABETES TYPE 2 ANIMAL MODEL

(57) Abstract: A diabetes type 2 model laboratory animal is disclosed which comprises cells over-expressing GRP40 under the control of the Ipf1/Pdx1 promoter. Also disclosed is the use of the model animal for the identification of agonists or antagonists towards GRP40, useful for the development of pharmaceuticals towards treatment of the disease.

CORRECTED VERSION

(19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 24 February 2005 (24.02.2005)

(10) International Publication Number WO 2005/015990 A1

(51) International Patent Classification7: A01K 67/027

(21) International Application Number:

PCT/SE2004/001209

(22) International Filing Date: 18 August 2004 (18.08.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18 August 2003 (18.08.2003) US 60/481,249 60/481,608 7 November 2003 (07.11.2003) US US 14 April 2004 (14.04.2004) 60/521,377

- (71) Applicants (for all designated States except US): BE-TAGENON AB [SE/SE]; P O Box 2339, S-103 18 STOCKHOLM (SE). YEDA RESEARCH AND DE-VELOPMENT CO LTD [IL/IL]; P O Box 95, 76100 REHOVOT (IL).
 - (72) Inventors; and
 - Inventors/Applicants (for US only): EDLUND, Helena [SE/SE]; Mellanbågen 18, S-907 38 UMEÅ (SE). WALKER, Michael D. [IL/IL]; 40 Sderot Hen, Apartment 12, 76469 REHOVOT (IL). RUBINS, Nir [IL/IL]; 2 Neve Alon Street, Apartment 29, 76455 REHOVOT (IL). STENEBERG, Pär [SE/SE]; Kustvägen 73, S-905 80 UMEÅ (SE).
 - (74) Agent: ALBIHNS STOCKHOLM AB; P.O. Box 5581, S-114 85 Stockholm (SE).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(48) Date of publication of this corrected version:

21 July 2005

(15) Information about Correction:

see PCT Gazette No. 29/2005 of 21 July 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW DIABETES TYPE 2 ANIMAL MODEL

(57) Abstract: A diabetes type 2 model laboratory animal is disclosed which comprises cells over-expressing GPR40 under the control of the Ipf1/Pdx1 promoter. Also disclosed is the use of the model animal for the identification of agonists or antagonists towards GPR40, useful for the development of pharmaceuticals towards treatment of the disease.